Maria Palasis sold $5,726 of LYRA
President & CEO at Lyra Therapeutics, Inc.. 1,702 shares at an average of $3.36, traded Jan 6, 2026, filed Jan 8, 2026.
Score components
- +25RoleCEO
- 0Trade size$6k at market
- 0Share of holdings soldSold 0.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -52.1%, 3m -86.1%, 6m -85.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-007751, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | SOpen-market sale Common Stock10b5-1 | -1,702 | $3.36 | $5,726 | 1,096,733 | Jan 8, 2026 |
Related signals
Other insiders at Lyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $2,587 769 shares | -0% | |
| 34Weak | LYRAsell Lyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $183k 45,875 shares | -28% | |
| 37Weak | LYRAsell Lyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $344k 70,390 shares | -31% | |
| 10Weak | Lyra Therapeutics, Inc. | Jason Cavalier Chief Financial Officer | $6,094 684 shares | -0% | |
| 13Weak | Lyra Therapeutics, Inc. | Maria Palasis President & CEO | $14k 1,565 shares | -0% | |
| 39Weak | LYRAbuy Lyra Therapeutics, Inc. | Harlan Waksal Executive Chair | $74k 25,000 shares | +11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.